In the published article, there was an error in the legend for Figure 3E. Due to an oversight, the IC50 value for LNCaP-NC was incorrectly reported as:
FIGURE 3.
ELOVL2 inhibition suppresses growth and restores enzalutamide sensitivity in resistant PCa cells. (A)Validation of ELOVL2 knockdown efficiency using three independent small interfering RNAs (siRNAs) by qRT-PCR and Western blot analysis. siRNA#3 showed the most potent knockdown effect and was selected for subsequent experiments. (B) Stable ELOVL2 knockdown using lentiviral shRNA (derived from siRNA#3 sequence). Knockdown efficiency was confirmed by qRT-PCR and Western blot. (C) Cell proliferation assessed by CCK-8 assay in C4-2-enzR and LNCaP-enzR cells following ELOVL2 knockdown. Data represent mean ± SD (n = 5), ***p < 0.001. (D) Colony formation assay demonstrating the proliferative capacity of C4-2-enzR and LNCaP-enzR cells after ELOVL2 inhibition. Colonies were counted after 14 days (mean ± SD, n = 3), *p < 0.05, ***p < 0.001. (E) Dose-response curves and calculated half-maximal inhibitory concentration (IC50) values for enzalutamide in ELOVL2-depleted cells. ELOVL2 knockdown significantly reduced IC50 values in both C4-2-enzR (32.78 µM, 95% CI: 27.95–37.54; ****p < 0.0001) and LNCaP-enzR (21.03 µM, 95% CI: 19.62–22.36; ****p < 0.0001) cells compared to control (C4-2-NC: 80.72 µM, 95% CI: 75.26–86.48; LNCaP-NC: 51.15 µM, 95% CI: 47.92–54.33).
“LNCaP-NC: 21.03 µM, 95% CI: 19.62–22.36.”
The corrected legend appears below.
“LNCaP-NC: 51.15 µM, 95% CI: 47.92–54.33.”
The authors apologize for this error and confirm that it does not affect the scientific conclusions of the article. The original article has been updated accordingly.
In the published article, there was an error in Figure 3E as presented. The visualization results for Figure 3E were correctly submitted and approved during the first round of revisions. However, due to an oversight on our part, this figure was inadvertently omitted in the second revised version. The corrected Figure 3E and its accompanying caption—Figure 3 ELOVL2 inhibition suppresses growth and restores enzalutamide sensitivity in resistant PCa cells—are provided below.
The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.